Context

This scoping review examines the current research on the effect of cannabis upon pain intensity in spinal cord injury (SCI) pain. Chronic pain is a significant secondary condition following SCI, and traditional treatments (e.g. opioids, NSAIDs) are often criticized for providing inadequate relief. As a result, there is increasing interest in and use of cannabis and cannabinoid-based medications as an alternative means of pain control.

Objective

The purpose of this review was to examine the scientific evidence on the effect of cannabis/cannabinoids upon pain intensity in SCI by mapping the current literature.

Methods

Two hundred and fifty-two studies were identified by searching electronic databases for articles published through February 2020. In addition, reviewers scanned the reference lists of identified articles and examined clinicaltrials.gov for unpublished data in this area. Title, abstract, and full-text reviews were completed by two independent reviewers. Data extraction was performed by a single reviewer and verified by a second reviewer.

Results

Six articles covering five treatment studies were included. Studies yielded mixed findings likely due to large variability in methodology, including lack of standardized dosing paradigms, modes of use, and duration of trial.

Conclusions

The current quality and level of evidence is insufficient to draw reliable conclusions of the efficacy of cannabis upon SCI-related pain itensity. We identify specific limitations of past studies and present guidelines for future research.

Trial registration: ClinicalTrials.gov identifier: Nct01606202..

中文翻译：

---

大麻对脊髓损伤患者疼痛强度影响的范围审查

语境

本范围审查审查了当前关于大麻对脊髓损伤 (SCI) 疼痛疼痛强度影响的研究。慢性疼痛是 SCI 后的重要继发性疾病，传统治疗（例如阿片类药物、非甾体抗炎药）经常因缓解不足而受到批评。因此，人们越来越关注和使用大麻和大麻素类药物作为控制疼痛的替代手段。

客观的

本综述的目的是通过绘制当前文献来检查关于大麻/大麻素对 SCI 疼痛强度影响的科学证据。

方法

通过在电子数据库中搜索截至 2020 年 2 月发表的文章，确定了 252 项研究。此外，审稿人扫描了已确定文章的参考列表，并检查了临床试验.gov 以获取该领域未发表的数据。标题、摘要和全文评审由两名独立评审员完成。数据提取由一名评审员执行，并由第二名评审员验证。

结果

包括六篇涵盖五项治疗研究的文章。研究产生了混杂的结果，可能是由于方法学的巨大差异，包括缺乏标准化的给药模式、使用模式和试验持续时间。

结论

目前的证据质量和水平不足以得出大麻对 SCI 相关疼痛强度的疗效的可靠结论。我们确定了过去研究的具体局限性，并为未来的研究提出了指导方针。

试用注册： ClinicalTrials.gov 标识符：Nct01606202。.